🇺🇸 Allogene Therapeutics, Inc.
Forum topic · ALLO · Company page: financials, ownership and filings
Join the discussion on Allogene Therapeutics, Inc.
Loading…
Results announced on 5 November 2026
Allogene Therapeutics, Inc. announced results on 5 November 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: a net loss of $50 million.
Insider trading in October 2026
Directors and officers of Allogene Therapeutics, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 1 insider sold shares worth about $48,698 in 1 trade.
Awards, option exercises and shares withheld for tax are not counted.
Mutual funds: 136 funds hold $201 million
136 mutual funds in 1 country hold shares of Allogene Therapeutics, Inc. worth $201 million, about 28.1% of the company (funds' newest reports, up to 31 July 2026).
Since their previous reports 91 funds added shares and 22 sold; on balance they bought $95 million. Share splits are not counted as trading.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.